Clinical Trials Logo

Optical Coherence Tomography clinical trials

View clinical trials related to Optical Coherence Tomography.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05517889 Completed - Clinical trials for Artificial Intelligence

Repeatability and Stability of Healthy Skin Features on OCT

Start date: September 1, 2022
Phase:
Study type: Observational

A test-retest study on the stability and repeatability of healthy skin features on OCT

NCT ID: NCT05223205 Completed - Macular Holes Clinical Trials

Optical Coherence Tomography Angiography Characteristics of Patients With Surgically Closed Full-thickness Idiopathic Macular Holes < 600 μm With Air Versus 10% SF6 Tamponade

Start date: July 6, 2020
Phase: N/A
Study type: Interventional

State of the art treatment for idiopathic macular holes consists of pars plana vitrectomy, internal limiting membrane staining with a blue colouring dye, internal limiting membrane peeling and filling of the vitrectomized space with a specific tamponade such as air and SF6. Air and SF6 have previously shown similar closure rates, although there was a trend towards lower closure rates in large diameter IMH (Idiopathic Macular Holes) using air. IMH with diameters < 600 μm are currently believed to have similar closure rates with air and SF6. The investigators want to assess possible effects of the used tamponade (air or SF6) on closure rates and perfusion parameters represented by OCTA (Optical coherence tomography angiography). IMH eyes with a minimum diameter > 600 μm will be excluded. Two idiopathic macular hole patient groups will therefore be formed: The first group (group 1) will receive air after vitrectomy and membrane peeling, the second group (group 2) will receive 10% SF6 (and 90% air) after vitrectomy and membrane peeling. After recruitment, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCT (Optical coherence tomography) and OCTA. Note: The trial was registered retrospectively on Clinicaltrials.gov after start of recruitment.

NCT ID: NCT04794634 Completed - Alzheimer Disease Clinical Trials

Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers

RETEVAL
Start date: March 9, 2021
Phase: N/A
Study type: Interventional

Alzheimer disease is hard, long and expensive to diagnose. In order to help the clinician, a new biomarker in Alzheimer disease seems to be very useful. The retina, as a window of the brain, could offer a new way to diagnose this common disease. Indeed, a retinal atrophy could especially appear in Alzheimer disease. Besides, many aspects about retinal alteration, visual function and their link with the disease deserve to be more explored. So as to fill these gaps, a new study about retinal specificity in Alzheimer disease appears to be relevant.

NCT ID: NCT04698902 Completed - Clinical trials for Coronary Artery Disease

Influence of Calcium Pattern on Plaque Modification Achieved With Intracoronary Lithotripsy

Start date: November 1, 2020
Phase:
Study type: Observational [Patient Registry]

Calcified coronary artery disease is a frequently encountered problem that can lead to poorer outcomes for patients undergoing PCI. Recently, intravascular lithotripsy has become available for the treatment of callcified coronary artery disease. The effect of intravascular lithotripsy on varying calcium patterns has not been adequately explored. This is an investigator initiated, open label, non-blinded, observational study involving a number of centers in Spain examining the effect of intravasuclar lithotripsy in varying calcium patterns. 100 patients wll be enrolled. Optical coherence tomography will be used to assess the effect of intravascular lithotripsy on varying calcium patterns (concentric, eccentric and nodular).

NCT ID: NCT03209843 Completed - Clinical trials for Ischemic Cardiomyopathy

Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO)

PERFECTO
Start date: March 7, 2018
Phase: N/A
Study type: Interventional

The objective of PERFECTO is to assess the reendothelialization at 3 months after successfully CTO percutaneous intervention (PCI) with new generation drug eluting stent (DES) by OFDI analysis. Designed as a multicentric, observational and prospective study which will be conducted at University Hospital of Poitiers (France), a systematic OFDI analysis will be realized immediately after CTO-PCI and at 3 months. Known as major predictive factors of stent thrombosis, percentages of malapposition, uncovered struts and neointimal hyperplasia proliferation will be measured over the entire length of each stent implanted combining in a composite primary endpoint.